AU2013358876B2 - Methods and compositions for inhibiting CNKSR1 - Google Patents

Methods and compositions for inhibiting CNKSR1 Download PDF

Info

Publication number
AU2013358876B2
AU2013358876B2 AU2013358876A AU2013358876A AU2013358876B2 AU 2013358876 B2 AU2013358876 B2 AU 2013358876B2 AU 2013358876 A AU2013358876 A AU 2013358876A AU 2013358876 A AU2013358876 A AU 2013358876A AU 2013358876 B2 AU2013358876 B2 AU 2013358876B2
Authority
AU
Australia
Prior art keywords
kras
cancer
compound
mut
cnksr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013358876A
Other languages
English (en)
Other versions
AU2013358876A1 (en
Inventor
Nathan T. Ihle
Martin INDARTE
D. Lynn Kirkpatrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHUSIS THERAPEUTICS Inc
Original Assignee
PHUSIS THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHUSIS THERAPEUTICS Inc filed Critical PHUSIS THERAPEUTICS Inc
Publication of AU2013358876A1 publication Critical patent/AU2013358876A1/en
Application granted granted Critical
Publication of AU2013358876B2 publication Critical patent/AU2013358876B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2013358876A 2012-12-14 2013-12-16 Methods and compositions for inhibiting CNKSR1 Active AU2013358876B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737658P 2012-12-14 2012-12-14
US61/737,658 2012-12-14
PCT/US2013/075505 WO2014093988A2 (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1

Publications (2)

Publication Number Publication Date
AU2013358876A1 AU2013358876A1 (en) 2014-06-19
AU2013358876B2 true AU2013358876B2 (en) 2018-05-10

Family

ID=50935099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013358876A Active AU2013358876B2 (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting CNKSR1

Country Status (7)

Country Link
US (1) US9340532B2 (enExample)
EP (1) EP2931280B1 (enExample)
JP (1) JP6357292B2 (enExample)
AU (1) AU2013358876B2 (enExample)
CA (1) CA2895162C (enExample)
MX (2) MX393754B (enExample)
WO (1) WO2014093988A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2895162C (en) 2012-12-14 2021-03-09 D. Lynn Kirkpatrick Methods and compositions for inhibiting cnksr1
US10227356B2 (en) 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
WO2018125983A1 (en) 2016-12-30 2018-07-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
CN110698411B (zh) * 2018-07-09 2023-05-09 四川大学 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途
US20230312482A1 (en) * 2020-07-28 2023-10-05 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2022187804A1 (en) * 2021-03-02 2022-09-09 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
WO2024192873A1 (zh) * 2023-03-20 2024-09-26 杭州天玑济世生物科技有限公司 一类具有萘胺结构的小分子化合物的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA775563A (en) 1968-01-09 Frank W. Horner Limited Hypoglycemic thiadiazoles
GB828963A (en) 1956-08-03 1960-02-24 Rhone Poulenc Sa Pharmaceutical compositions containing 2-p-aminobenzenesulphonamido-5-t-butyl-1, 3, 4-thiadiazole
US3821222A (en) 1971-11-22 1974-06-28 Chevron Res Hydrocarbyl sulfenylmercapto pyrimidines
US4017489A (en) 1975-07-10 1977-04-12 The Goodyear Tire & Rubber Company Process of preparing unsymmetrical disulfides
DE2556011A1 (de) 1975-12-12 1977-06-23 Merck Patent Gmbh Disulfide
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
GB2152497B (en) 1983-11-28 1987-08-05 Otsuka Kagaku Kk Process for the preparation of azetidinone derivatives
FR2573077B1 (fr) 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
GB9507415D0 (en) * 1994-06-08 1995-05-31 Zylepsis Ltd Production and uses of caffeic acid and derivatives thereof
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
WO2002083064A2 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
NZ531245A (en) * 2001-08-15 2005-09-30 Icos Corp 2H-phthalazin-1-ones and methods for use thereof
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20060142178A1 (en) 2002-04-08 2006-06-29 Barnett Stanley F Method of treating cancer
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP4787155B2 (ja) 2003-06-24 2011-10-05 イシス イノベーション リミテッド タンパク質のジスルフィド結合形成およびグリコシル化の方法とそれに用いられる試薬
BRPI0412380A (pt) 2003-07-08 2006-09-19 Novartis Ag compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
CA2559579A1 (en) 2004-03-19 2005-09-29 The Tapemark Company Thermoplastic films and methods for making
JP2007530589A (ja) 2004-03-26 2007-11-01 アンフォラ ディスカバリー コーポレーション 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
ATE487706T1 (de) 2005-10-06 2010-11-15 Sanofi Aventis Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2007106391A1 (en) 2006-03-10 2007-09-20 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
KR20090017498A (ko) 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Ｐｉ３ 키나제 길항물질
CA2674078C (en) 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
CA2721371C (en) 2008-04-14 2016-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2010085968A1 (en) * 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
CN102448951B (zh) * 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
CA2773561A1 (en) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
KR20140027974A (ko) * 2011-04-05 2014-03-07 버텍스 파마슈티칼스 인코포레이티드 Ｔｒａ 키나제의 억제제로서 유용한 아미노피라진 화합물
CA2895162C (en) 2012-12-14 2021-03-09 D. Lynn Kirkpatrick Methods and compositions for inhibiting cnksr1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 883050-71-3; STN Entry Date 05 May 2006; ,4-dihydro-3-[[4-(4-nitrophenyl)-2-thiazolyl]methyl]-4-oxo-1-Phthalazineacetic acid ethyl ester *
CAS Registry Number 883052-65-1; STN Entry Date 05 May 2006; 3,4-dihydro-4-oxo-3-[[4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]methyl]- 1-Phthalazineacetic acid ethyl ester *

Also Published As

Publication number Publication date
US9340532B2 (en) 2016-05-17
WO2014093988A2 (en) 2014-06-19
US20150307482A1 (en) 2015-10-29
JP2016508969A (ja) 2016-03-24
MX372739B (es) 2020-05-06
WO2014093988A3 (en) 2014-08-07
EP2931280B1 (en) 2018-02-14
CA2895162A1 (en) 2014-06-19
MX393754B (es) 2025-03-24
CA2895162C (en) 2021-03-09
AU2013358876A1 (en) 2014-06-19
MX2015007608A (es) 2016-04-13
EP2931280A2 (en) 2015-10-21
EP2931280A4 (en) 2016-06-01
JP6357292B2 (ja) 2018-07-11

Similar Documents

Publication Publication Date Title
AU2013358876B2 (en) Methods and compositions for inhibiting CNKSR1
Vakifahmetoglu-Norberg et al. Pharmacologic agents targeting autophagy
Li et al. Discovery of N 1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo [2, 3-d] pyrimidin-2-yl) amino) phenyl)-N 8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
Spano et al. Pyrrolo [2′, 3′: 3, 4] cyclohepta [1, 2-d][1, 2] oxazoles, a new class of antimitotic agents active against multiple malignant cell types
Garofalo et al. Selective inhibitors of G2019S-LRRK2 kinase activity
ES2780382T3 (es) Derivados de pirazolopirimidina
ES2487623T3 (es) Derivados de 6,7,8,9-tetrahidro-pirimido{1,2-a}pirimidin-4-ona, su preparación y su aplicación farmacéutica
CN105143221A (zh) 用于治疗炎性障碍的化合物及其药物组合物
ES2627428T3 (es) Nuevos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona, su preparación y su utilización farmacéutica
US12306164B2 (en) Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases
CA2983260C (en) Sulfonamide compounds, compositions and methods for inhibiting cnksr1
AU2018201292B2 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof
Zaręba et al. Low-basicity 5-HT6 receptor ligands from the group of cyclic arylguanidine derivatives and their antiproliferative activity evaluation
EP4654972A1 (en) Compounds and methods for yap/tead modulation and indications therefor
Wood Chemical synthesis and use of in silico methods for the rational design of small molecule anti-cancer therapeutic candidates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)